Differential Activation of Cultured Neonatal Cardiomyocytes by Plasmalemmal Versus Intracellular G Protein-coupled Receptor 55*

Received for publication, January 23, 2013 and in revised form, June 23, 2013 Published, JBC Papers in Press, June 27, 2013, DOI 10.1074/jbc.M113.456178

Justine Yu†, Elena Deliu‡, Xue-Quian Zhang†, Nicholas E. Hoffman§, Rhonda L. Carter†, Laurel A. Grisanti‡, G. Cristina Brailoiu‡, Muniswamy Madesh‡, Joseph Y. Cheung§, Thomas Force¶, Mary E. Abood‡**, Walter J. Koch†, Douglas G. Tilley‡, and Eugen Brailoiu‡

From the †Center for Translational Medicine, ‡Department of Pharmacology, §Division of Nephrology, ¶Department of Internal Medicine, **Department of Anatomy and Cell Biology, and ‡‡Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, Pennsylvania 19140 and the ‡Department of Pharmaceutical Sciences, Thomas Jefferson University, Jefferson School of Pharmacy, Philadelphia, Pennsylvania 19107

Background: The LPI-sensitive receptor GPR55 signals through Ca2+. Results: Activation of sarcolemmal versus intracellular GPR55 mobilizes Ca2+ from distinct pools and associates with cardiomyocyte depolarization and hyperpolarization, respectively. Conclusion: GPR55 location critically affects LPI-induced modulation of cardiomyocyte function. Significance: We identify GPR55 as a new receptor regulating cardiac function at two cellular sites.

The L-α-lysophosphatidylinositol (LPI)-sensitive receptor GPR55 is coupled to Ca2+ signaling. Low levels of GPR55 expression in the heart have been reported. Similar to other G protein-coupled receptors involved in cardiac function, GPR55 may be expressed both at the sarcolemma and intracellularly. Thus, to explore the role of GPR55 in cardiomyocytes, we used calcium and voltage imaging and extracellular administration or intracellular GPR55 ligands. We provide the first evidence that, in cultured neonatal ventricular myocytes, LPI triggers distinct signaling pathways via GPR55, depending on receptor localization. GPR55 activation at the sarcolemma elicits, on one hand, Ca2+ entry via L-type Ca2+ channels and, on the other, inositol 1,4,5-trisphosphate-dependent Ca2+ release. The latter signal is further amplified by Ca2+-induced Ca2+ release via ryanodine receptors. Conversely, activation of GPR55 at the membrane of intracellular organelles promotes Ca2+ release from acidic-like Ca2+ stores via the endolysosomal NAADP-sensitive two-pore channels. This response is similarly enhanced by Ca2+-induced Ca2+ release via ryanodine receptors. Extracellularly applied LPI produces Ca2+-independent membrane depolarization, whereas the Ca2+ signal induced by intracellular microinjection of LPI converges to hyperpolarization of the sarcolemma. Collectively, our findings point to GPR55 as a novel G protein-coupled receptor regulating cardiac function at two cellular sites. This work may serve as a platform for future studies exploring the potential of GPR55 as a therapeutic target in cardiac disorders.

A putative role for GPR55 in physiology and disease is beginning to emerge. For instance, accumulating evidence supports its involvement in inflammatory and neuropathic pain (1), bone mass preservation (2), obesity (3), or cancer (4–7). Additional functional implications of GPR55 may be inferred from its widespread distribution throughout the body (8, 9), including the heart (8). Although it serves as target for several cannabinoid ligands, GPR55 appears to be endogenously activated by L-α-lysophosphatidylinositol (LPI) (10, 11). Because LPI is generated intracellularly, mainly by the Ca2+-dependent cytoplasmic phospholipase A2 (cPLA2) (12), and because modulation of this enzyme has important pathophysiological implications in the ischemic heart (13, 14), we hypothesized a role for LPI and GPR55 in the myocardium. Cardiomyocyte physiology is critically regulated by Ca2+ and Ca2+-dependent electrical processes (15). Increases in intracellular Ca2+ concentration as well as alterations in ion currents and membrane properties have been correlated previously with GPR55 activation (16–18). Considering the emerging paradigm of functional intracellular G protein-coupled receptors (GPCRs) (19, 20), which has also been suggested for the receptors of other lipid mediators (21) and for cannabinoid receptors (22–25), we postulated that a GPR55-dependent signaling pathway may be initiated either at the plasma membrane or intracellularly.

**The abbreviations used are: LPI, L-lysophosphatidylinositol; GPCR, G protein-coupled receptor; LTCC, L-type Ca2+ channel; IP3R, inositol 1,4,5-trisphosphate receptor; TPC, two-pore channel; CICR, Ca2+-induced Ca2+ release; RyR, ryanodine receptor; SR, sarcoplasmic reticulum; IP3, inositol 1,4,5-trisphosphate; NAADP, nicotinic acid adenine dinucleotide phosphate; RFP, red fluorescent protein.
within the cell. Thus, we used Ca\(^{2+}\) and voltage imaging and both extracellular and intracellular administration (microinjection) of GPR55 ligands to test the involvement of this receptor in the regulation of cardiomyocyte signaling.

**EXPERIMENTAL PROCEDURES**

**Chemicals**—LPI (soy, sodium salt) was purchased from Avanti Polar Lipids (Alabaster, AL), ryanodine and xestospongin C from EMD Millipore (Billerica, MA), ML-193 from Hit2Lead (San Diego, CA), and Ned-19 from Tocris Bioscience (R&D Systems, Minneapolis, MN). Unless stated otherwise, all other chemicals were from Sigma. LPI and ML-193 (100 mM stock solution) were dissolved in dimethyl sulfoxide.

**Primary Neonatal Cardiomyocyte Culture**—Cardiomyocyte cultures were prepared from 1- to 2-day-old Sprague-Dawley rats (Harlan Laboratories, Indianapolis, IN) by enzymatic digestion. Hearts were excised and placed in a sterile solution containing 116 mM NaCl, 20 mM HEPES, 0.08 mM Na\(_2\)HPO\(_4\), 56 mM glucose, 5.4 mM KCl, and 0.8 mM MgSO\(_4\)•7H\(_2\)O (pH 7.35). Blood and connective tissues were removed and ventricles minced and subjected to 5–15 min of enzymatic digestion with collagenase II (Worthington, Lakewood, NJ) and pancreatin. Fibroblasts were removed by preplating for 2 h. Following enrichment, cardiomyocytes were cultured overnight in F-10 medium (Mediatech, Manassas, VA) containing 10% horse serum, 5% FBS, and 1% penicillin/streptomycin/amphotericin B solution (Invitrogen) at 37 °C in a humidified incubator with 5% CO\(_2\). Sera were attained from Gemini Bio-Products (West Sacramento, CA). The following day, medium was replaced with F-10 medium containing 5% FBS and 1% PSF.

**Real-time PCR**—Total RNA was isolated from isolated rat neonatal cardiomyocytes, cortex, and olfactory bulb using an RNeasy Midi kit or RNeasy Fibrous Tissue Midi kit with proteinase K and DNase I digestion (Qiagen). cDNA was synthesized using a high-capacity cDNA reverse transcription kit (Applied Biosystems), and real-time PCR was performed with TaqMan® gene expression master mix (Applied Biosystems) using the StepOne Plus real-time PCR system (Applied Biosystems). The following primer were used: Rn03037213-s1 (GPR55) and Rn01775763-g1 (GAPDH for normalization).

**Intracellular Microinjection**—Injections were performed using the Femtotips II, InjectMan NI2, and FemtoJet systems (Eppendorf) as reported previously (24, 28, 29). Pipettes were backfilled with an intracellular solution containing 110 mM KCl, 10 mM NaCl, 20 mM HEPES (pH 7.2), and dimethyl sulfoxide 0.004% (31) or the compounds to be tested. The injection time was 0.4 s at 60 hectaropiscals with a compression pressure of 20 hectaropiscals to maintain the microinjected volume to less than 1% of cell volume, as measured by microinjection of a fluorescent compound (Fura-2 free acid) (31). The intracellular concentration of chemicals was determined on the basis of the concentration in the pipette and the volume of injection.

**Measurement of Membrane Potential**—The relative changes in membrane potential of single cardiomyocytes were evaluated using bis-(1,3-dibutylbarbituric acid) trimethine oxonol, bis-(1,3-dibutylbarbituric acid) trimethine oxonol, a slow-response, voltage-sensitive dye, as described previously (32–34). Upon membrane hyperpolarization, the dye concentrates in the cell membrane, leading to a decrease in fluorescence intensity, whereas depolarization induces the sequestration of the dye into the cytosol, resulting in an increase of the fluorescence intensity (35). Cultured ventricular cardiomyocytes were incubated for 30 min in Hanks’ balanced salt solution containing 0.5 mM bis-(1,3-dibutylbarbituric acid) trimethine oxonol, and fluorescence was monitored at 0.17 Hz (excitation/emission 480 nm/540 nm). Calibration of bis-(1,3-dibutylbarbituric acid) trimethine oxonol fluorescence following background subtraction was performed using the Na\(^{+}\)-K\(^{+}\) ionophore gramicidin in Na\(^{+}\)-free physiological solution and various concentrations of K\(^{+}\) (to alter membrane potential) and N-methylglucamine (to maintain osmolality) (35). Under these conditions, the membrane potential is approximately equal to the K\(^{+}\) equilibrium potential determined by the Nernst equation. The intracellular K\(^{+}\) and Na\(^{+}\) concentration were assumed to be 130 mM and 10 mM, respectively.

**Electrophysiology**—Briefly, pipettes were pulled from tubing with an outer diameter of 1.5 mm (Garner Glass, Claremont, CA). After fire polishing and backfilling, pipette resistances were ~3–5 MΩ. Membrane potentials from rat neonatal myocytes were recorded using current-clamp configuration with
Axopatch-200B patch-clamp amplifier (Axon Instruments, Foster City, CA) and pCLAMP 10 software. The pipette solution consisted of 125 mM KCl, 4 mM MgCl₂, 0.06 mM CaCl₂, 10 mM HEPES, 5 mM K-EGTA, 3 mM Na₂ATP, and 5 mM Na₂creatine phosphate (pH 7.2). The external solution consisted of 132 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl₂, 1.8 mM MgCl₂, 0.6 mM NaH₂PO₄, 7.5 mM HEPES, 7.5 mM Na-HEPES, and 5 mM glucose (pH 7.4).

Statistics—Data were expressed as mean ± S.E. One-way analysis of variance, followed by post hoc Bonferroni and Tukey tests, were used to assess significant differences between groups. Mann–Whitney U test was used for comparison of the traces shown in Fig. 4A. p < 0.05 was considered statistically significant.

RESULTS

Extracellular Administration of LPI Elicits GPR55-dependent Cytosolic Ca²⁺ Elevation in Ventricular Cardiomyocytes, Which Is Partially Contingent on Ca²⁺ Entry—To initially determine whether GPR55 activation can elevate cytosolic Ca²⁺ in cultured neonatal ventricular myocytes, the cells were stimulated with increasing concentrations of LPI in the absence and presence of a GPR55 antagonist. The cardiomyocytes responded to a bath application of LPI (0.1, 1 and 10 μM) with a concentration-dependent increase in [Ca²⁺], of 12 ± 2.6 nm (n = 17 cells), 94 ± 3.8 nm (n = 23), and 727 ± 8.4 nm (n = 19). The effects reached statistical significance (p < 0.05) for concentrations of 1 and 10 μM (Fig. 1A). LPI induced a sustained Ca²⁺ response that was relatively slow in onset, with 1- to 2-min latency, and reached a maximum within 3–4 min (Fig. 1, B and C). Pretreatment with the GPR55 antagonist ML-193 (30 μM, 10 min) (36) significantly attenuated the effect of LPI (10 μM), supporting GPR55 dependence of the response (Δ[Ca²⁺], was 21 ± 6.2 nm; n = 26; Fig. 1, B and C). In the presence of nifedipine (NIF), the effect of extracellular LPI (10 μM) was reduced to 348 ± 7.4 nm, indicating partial involvement of L-type Ca²⁺ channels (LTCC) (Fig. 1, A and B). Expression of GPR55 in rat neonatal cardiomyocytes was confirmed relative to positive control brain tissue samples via real-time PCR, revealing a substantially lower gene expression level than that found in either cortex or olfactory bulb tissue (Fig. 2), consistent with another report showing high levels of GPR55 expression in various brain regions and low GPR55 mRNA levels in the whole heart (8).

Activation of GPR55 at the Plasma Membrane Mobilizes Ca²⁺ from the sarcoplasmic reticulum—When cultured neonatal cardiomyocytes were incubated with Ca²⁺-free saline, extracellular application of LPI (10 μM) produced a transient increase in [Ca²⁺] by 314 ± 6.1 nm (n = 19; Fig. 3A, B), which was sensitive to IP₃R blockade with heparin and xestospongin C (Δ[Ca²⁺] = 8 ± 1 nm, n = 31). The response to LPI was largely unaffected by pretreatment with Ned-19 (1 μM, 15 min), which blocks two-pore channels (TPCs) and subsequent NAADP-dependent Ca²⁺ release from the endoplasmic reticulum (37) (Δ[Ca²⁺] = 308 ± 6.7 nm, n = 16, Fig. 3). In the presence of ryanodine (10 μM, 30-min incubation), the response to LPI was reduced but not abolished (Δ[Ca²⁺] = 126 ± 3.7 nm, n = 24), indicating an amplification of the IP₃-dependent signal via Ca²⁺-induced Ca²⁺ release (CICR) and ryanodine receptors (RyR) (Fig. 3).

Ryanodine inhibits Ca²⁺ mobilization either by blocking Ca²⁺ release channels or by promoting the leakage of Ca²⁺ from the SR (38). To distinguish between these possibilities, we treated neonatal cardiomyocytes with thapsigargin (1 μM in Ca²⁺-free saline), an inhibitor of the sarco/endoplasmic reticulum Ca²⁺ ATPase, conditions which deplete both ryanodine- and IP₃-sensitive Ca²⁺ pools (39). As shown in Fig. 4, A–D, application of thapsigargin (1 μM) increased the fluorescence ratio (340/380 nm) of Fura-2 AM-loaded neonatal cardiomyo-
cytes with similar amplitudes and kinetics in the absence and presence of ryanodine (10 μM, 30 min). Should ryanodine promote the basal Ca\(^{2+}\) leak from the SR, this would result in a reduced SR Ca\(^{2+}\) store level, further manifested as a significantly lower Ca\(^{2+}\) response to thapsigargin in ryanodine-treated versus untreated cells. Moreover, in Ca\(^{2+}\)-free saline, neonatal cardiomyocytes pretreated with ryanodine (10 μM, 30 min) did not respond to caffeine (10 mM) with an increase in [Ca\(^{2+}\)]\(_i\) (Fig. 4, A and B). Caffeine is known to release intracellular Ca\(^{2+}\) by targeting RyRs in various cell types, including neonatal cardiomyocytes (40). In view of these findings, we conclude that the effects of ryanodine (10 μM, 30 min) observed in our study are due to inhibition of ryanodine receptors.

Several control experiments (n = 6 cells/experiment) were performed to ensure that inhibition of LPI-induced Ca\(^{2+}\) responses was due to ML-193 antagonism at GPR55 rather than off-target effects at Ca\(^{2+}\) entry or Ca\(^{2+}\) release channels. High concentrations of KCl produce depolarization-induced activation of LTCCs in cardiomyocytes (41). As shown in Fig. 5, the Ca\(^{2+}\) response of cultured neonatal ventricular cardiomyocytes to 50 mM KCl was largely identical in shape and amplitude in the absence and presence of ryanodine (10 μM, 30 min). Should ryanodine promote the basal Ca\(^{2+}\) leak from the SR, this would result in a reduced SR Ca\(^{2+}\) store level, further manifested as a significantly lower Ca\(^{2+}\) response to thapsigargin in ryanodine-treated versus untreated cells. Moreover, in Ca\(^{2+}\)-free saline, neonatal cardiomyocytes pretreated with ryanodine (10 μM, 30 min) did not respond to caffeine (10 mM) with an increase in [Ca\(^{2+}\)]\(_i\) (Fig. 4, A and B). Caffeine is known to release intracellular Ca\(^{2+}\) by targeting RyRs in various cell types, including neonatal cardiomyocytes (40). In view of these findings, we conclude that the effects of ryanodine (10 μM, 30 min) observed in our study are due to inhibition of ryanodine receptors.

Several control experiments (n = 6 cells/experiment) were performed to ensure that inhibition of LPI-induced Ca\(^{2+}\) responses was due to ML-193 antagonism at GPR55 rather than off-target effects at Ca\(^{2+}\) entry or Ca\(^{2+}\) release channels. High concentrations of KCl produce depolarization-induced activation of LTCCs in cardiomyocytes (41). As shown in Fig. 5, the Ca\(^{2+}\) response of cultured neonatal ventricular cardiomyocytes to 50 mM KCl was largely identical in shape and amplitude in the absence and presence of ryanodine (10 μM, 30 min). Should ryanodine promote the basal Ca\(^{2+}\) leak from the SR, this would result in a reduced SR Ca\(^{2+}\) store level, further manifested as a significantly lower Ca\(^{2+}\) response to thapsigargin in ryanodine-treated versus untreated cells. Moreover, in Ca\(^{2+}\)-free saline, neonatal cardiomyocytes pretreated with ryanodine (10 μM, 30 min) did not respond to caffeine (10 mM) with an increase in [Ca\(^{2+}\)]\(_i\) (Fig. 4, A and B). Caffeine is known to release intracellular Ca\(^{2+}\) by targeting RyRs in various cell types, including neonatal cardiomyocytes (40). In view of these findings, we conclude that the effects of ryanodine (10 μM, 30 min) observed in our study are due to inhibition of ryanodine receptors.
presence of 30 μM ML-193 (the Δ[Ca^{2+}]i was 523 ± 5.4 nM). Angiotensin II (100 nM), which activates IP3 production in the heart (42), also induced similar Ca^{2+} responses in the two paradigms: the Δ[Ca^{2+}]i was 192 ± 2.7 nM in the absence of ML-193 and 188 ± 3.1 nM in the presence of ML-193 (30 μM) (Fig. 5, A and B). Cardiac activation of β-adrenoreceptors with isoproterenol has recently been shown to produce cyclic ADP-ribose and NAADP (43), second messengers that activate RyRs and TPCs, respectively (44, 45). Isoproterenol (100 nM) elevated the [Ca^{2+}]i of neonatal ventricular myocytes with similar amplitudes in the absence (the Δ[Ca^{2+}]i was 283 ± 4.8 nM) and presence of 30 μM ML-193 (the Δ[Ca^{2+}]i was 267 ± 4.1 nM, Fig. 5, A and B). Thus, the absence of the LPI-induced Ca^{2+} response in cultured cardiomyocytes treated with ML-193 is not due to off-target effects at LTCCs, IP3Rs, RyRs, or TPCs.

Microinjection of LPI Elevates the [Ca^{2+}]i of Cultured Neonatal Ventricular Cardiomyocytes upon Activation of Intracellular GPR55—To examine the presence and functionality of intracellular GPR55 in cultured ventricular cardiomyocytes, cells underwent intracellular microinjection with LPI in the absence or presence of ML-193. The [Ca^{2+}]i of ventricular myocytes was not modified significantly by control buffer microinjection (the Δ[Ca^{2+}]i was 34 ± 6 nM, n = 6; Fig. 6, A–C), whereas intracellular administration of LPI (0.01, 0.1 and 1 μM) triggered [Ca^{2+}]i elevations of 36 ± 4 nM, 83 ± 6.9 nM (p < 0.05), and 492 ± 7 nM (p < 0.05), respectively (n = 6 for each concentration tested, Fig. 6A). LPI produced a fast, robust, and transitory increase in [Ca^{2+}]i (Fig. 6, B and D), sensitive to intracellular blockade of GPR55 with ML-193 (3 μM; the Δ[Ca^{2+}]i was 57 ± 11 nM; n = 6; Fig. 6, A, B, and E). To exclude any possible involvement of plasmalemmal GPR55 in LPI-induced responses, ML-193 (30 μM, 1-min incubation) was also present in the extracellular solution. Blockade of intracellular GPR55 was a mandatory step to prevent the effect of microinjected LPI because the extent to which ML-193 crosses the sarcolemma even after 10 min of incubation is not sufficient to completely abolish the Ca^{2+} response of cultured neonatal ventricular myocytes to intracellular LPI. 10-min incubation with ML-193 reduces the LPI-induced effect on [Ca^{2+}]i from 492 ± 7 nM to 213 ± 44 nM, n = 6 cells (Fig. 6, F and G). Conversely, a 10-min incubation with ML-193 was sufficient to block the effect of extracellular LPI (Fig. 1).

The Ca^{2+} Release Triggered by Intracellular Microinjection of LPI is NAADP-dependent—In the absence of extracellular Ca^{2+}, intracellular injection of LPI (1 μM) into cultured ventricular myocytes elicited a fast and transient elevation of [Ca^{2+}]i by 477 ± 11 nM, insensitive to IP3R blockade with heparin and xestospongin C (Δ[Ca^{2+}]i = 468 ± 16 nM), diminished by ryanodine pretreatment (10 μM, 30 min, Δ[Ca^{2+}]i = 184 ± 6 nM), and largely abolished in the presence of Ned-19 (1 μM, 15 min, Δ[Ca^{2+}]i = 36 ± 7 nM) (Fig. 7, n = 6 cells/experiment). These findings suggest that NAADP-dependent lysosomal Ca^{2+} stores are critically involved in LPI signaling upon activation of intracellularly located GPR55. This signal is further amplified by CICR via RyR.

Intracellular GPR55 Is Located at Endolysosomes in Neonatal Rat Cardiomyocytes—Extensive colocalization was observed when GFP-tagged GPR55 was coexpressed with RFP-tagged Rab7, a small GTPase associated with both endosomes and lysosomes (46). When cells where incubated with bafilomycin A1, a V-type ATPase that prevents lysosomal acidification (47), the GPR55 and Rab7 signal was abolished, confirming endolysosomal location of intracellular GPR55 (Fig. 8).

Antipodal Changes in Resting Membrane Potential in Response to Intracellular LPI Administration to Cultured Neonatal Ventricular Myocytes and Relation to LPI-induced Changes in [Ca^{2+}]i—Cultured cardiomyocytes had a mean resting membrane potential of −72.7 ± 0.05 mV. An extracellular application of LPI (10 μM) produced a relatively long-lasting membrane depolarization with a mean amplitude of 12.6 ± 0.7 mV (n = 17) that was abolished by pretreatment with ML-193 (30 μM, ΔV_m = 0.9 ± 0.3 mV, Fig. 9, A and B) (n = 11). Conversely, intracellular microinjection of LPI (1 μM) to ventricular myocytes resulted in a rapid, short-lived hyperpolarization with a mean amplitude of −7.3 ± 0.5 mV (Fig. 9, A and B) (n = 6). Similar to the plasma membrane-initiated response, the effect of microinjected LPI was sensitive to GPR55 blockade with ML-193 (3 μM). In the presence of the GPR55 antagonist, microinjection of LPI (1 μM) elicited an insignificant response (ΔV_m = −1.2 ± 0.3 mV, n = 6) largely...
similar to that of control buffer microinjection ($\Delta V_{m} = -0.9 \pm 0.2$ mV, $n = 6$, Fig. 9, A and B). To evaluate how the GPR55-dependent $\text{Ca}^{2+}$ signaling correlates with the voltage changes observed in this study, cells were loaded with BAPTA-AM (20 $\mu$M, 20 min), a potent $\text{Ca}^{2+}$ chelator. As expected, BAPTA-

FIGURE 6. Intracellular GPR55 stimulation elevates $[\text{Ca}^{2+}]_{i}$ in cultured neonatal ventricular cardiomyocytes. A, comparison of the increases in $[\text{Ca}^{2+}]_{i}$ produced by the microinjection of control buffer LPI (0.01, 0.1, and 1 $\mu$M) and of LPI (1 $\mu$M) in the presence of ML-193 (3 $\mu$M). *, $p < 0.05$ compared with control; #, $p < 0.05$ compared with 1 $\mu$M LPI. B, averaged $\text{Ca}^{2+}$ responses ($n = 6$) of ventricular myocytes to intracellular administration of control buffer (black) or of LPI (1 $\mu$M) in the absence (blue) or presence of ML-193 (3 $\mu$M, red). C–E, typical fluorescence images of Fura-2 AM-loaded cardiomyocytes before (left panels), during (center panels), and 6 min after (right panels) intracellular administration of control buffer (C), 1 $\mu$M LPI alone (D), or in presence of ML-193 (E). The arrows indicate the injected cells. The fluorescence scale (0–3) is illustrated in each panel and magnified in the first panel of C. F, comparison of the increases in $[\text{Ca}^{2+}]_{i}$ produced by microinjected LPI (1 $\mu$M) alone or after 10-min incubation with ML-193 (3 $\mu$M). G, averaged $\text{Ca}^{2+}$ responses ($n = 6$ cells) of ventricular myocytes to intracellular administration of LPI (1 $\mu$M) in the absence (black) or presence of extracellular ML-193 (30 $\mu$M, 10-min incubation, red).
injected LPI from 492 ± 7 nm (n = 6) to 11 ± 2.7 (n = 6 cells). However, even in the presence of BAPTA-AM, a bath application of LPI (10 μM) resulted in a depolarization of 12.79 ± 0.8 mV (n = 12) similar to that observed in the absence of BAPTA-AM pretreatment (Fig. 9, A and B). Conversely, LPI (1 μM) microinjection to BAPTA-AM-incubated neonatal cardiomyocytes did not significantly modify sarcolemmal potential (the ΔV_m was −1.1 ± 0.3 mV; n = 9 cells; Fig. 9, A and B). In patch-clamp experiments, a bath application of LPI (10 μM) did not trigger action potential but produced a 10.2 ± 3.2 mV (n = 6 cells) depolarization of cardiomyocyte membrane similar to that observed using voltage-sensitive dyes (Fig. 9, E and F).

**DISCUSSION**

GPCR signaling in the heart has important physiological and pathological implications (48). Cardiac cell processes such as contractility, response to ischemia, proliferation, apoptosis, and gene expression are GPCR-regulated, making GPCRs an important therapeutic target in a variety of heart diseases (49, 50). Importantly, in addition to the “classical” GPCRs involved in heart function, such as those for angiotensin II, endothelin 1, or catecholamines (48, 49), a wide variety of recently deorphana-
[Ca^{2+}], may also induce gene expression and transcription, eliciting hypertrophic responses, a process occurring on a longer time scale and known as excitation-transcription coupling (15). In both processes, a major role is played by Ca^{2+} release from internal stores (52), although it was shown recently that the latter is also triggered by Ca^{2+} influx (53). Thus, identification of the Ca^{2+} pools mobilized by LPI is critical for the characterization of the GPR55-initiated signaling pathways in ventricular cardiomyocytes.

We noticed that LTCC blockade reduced to half the effect of bath-applied LPI on [Ca^{2+}]. Moreover, the response was rather brief and no longer showed a plateau phase. Likewise, in the absence of extracellular Ca^{2+}, LPI application induced a transient [Ca^{2+}], rise with a decreased amplitude. Thus, both Ca^{2+} entry and Ca^{2+} release occur downstream of sarcolemmal GPR55 activation in cultured neonatal ventricular cardiomyocytes. In addition to the endo/sarcoplasmic reticulum, which expresses Ca^{2+} release channels such as IP_{3}R and RyR (54), the endolysosomal system also functions as a Ca^{2+} store involved in Ca^{2+} mobilization (45, 55).

Using a pharmacological approach, we demonstrate that Ca^{2+} release occurs primarily via IP_{3}Rs and is further amplified by a RyR-dependent CICR mechanism, whereas the endolysosomal NAADP-dependent Ca^{2+} stores are not involved. The IP_{3} dependence of the response is not surprising because GPR55 has been shown to couple with Gq (51). Compared with RyR, IP_{3}R expression is scarce in ventricular myocytes, indicating a rather minor physiological role. While IP_{3}R activation
may be beneficial in that it serves as an inotropic support for ventricles, its predominant effect is to promote arrhythmias (56, 57). To explain the increased arrhythmogenicity of IP₃ stimulation, it has been suggested that Ca²⁺ release via IP₃Rs may activate additional currents such as the store-operated Ca²⁺ currents or the Na⁺/Ca²⁺ exchange current (56). These currents may be partially responsible for the plateau phase of the Ca²⁺ response elicited by extracellular application of LPI to cultured neonatal ventricular myocytes incubated with Ca²⁺-containing saline. On a different note, studies on adult and neonatal cardiomyocytes correlated both Ca²⁺ influx via LTCC (53) and the IP₃-dependent Ca²⁺ release with cardiac hypertrophy and heart failure (52, 57–59), suggesting that sarcolemmal GPR55 activation may produce hypertrophic signals.

Because cardiovascular cell function is also regulated by intracellularly expressed GPCRs (60, 61) and preliminary data from our laboratory suggested functionality of intracellular GPR55 (23), we evaluated the effect of LPI microinjection in cultured neonatal ventricular myocytes. Similar to the response elicited at the plasma membrane, the [Ca²⁺]ᵢ elevation triggered by intracellular injection of LPI was GPR55-dependent. However, the Ca²⁺ response pattern was strikingly different in the two paradigms. Extracellular administration of LPI resulted in a relatively slow response that reached a peak within 1–2 min and continued with a plateau phase, whereas LPI microinjection induced a fast and transitory effect similar to that reported upon activation of other intracellular GPCRs, such as those for angiotensin II (29, 33, 62) or endothelin 1 (28). We have noticed likewise discrepancies in the plasmalemmal-initiated versus intracellularly initiated Ca²⁺ responses by the G protein-coupled estrogen receptor GPER/GPR30 (30, 63), which is reportedly expressed at both sites (64, 65). LPI is a lipid messenger, expected to get partitioned in the lipid bilayer and reach the other side of the sarcolemma. However, LPI cannot passively diffuse across the plasma membrane. Rather, after its intracellular synthesis by the phospholipase A2, LPI is pumped out of the cell via the multidrug resistance-associated protein 1 (Mrp1/ABCC1) (7). Mrp1 is also expressed in the sarcolemma of rodent heart (66, 67).

Furthermore, we found that the [Ca²⁺]ᵢ rise produced by intracellular administration of LPI is completely contingent on Ca²⁺ mobilization from internal stores. Importantly, the Ca²⁺ is released from the endolysosomes via the NAADP-sensitive TPCs (45, 55), a signal further amplified by RyR-dependent CICR from the sarcoplasmic reticulum. NAADP-dependent Ca²⁺ release from acidic stores has been shown to elevate the sarcoplasmic reticulum Ca²⁺ load, thus enhancing cardiomyocyte contraction (68). Moreover, β-adrenoceptors in ventricular myocytes can signal through NAADP (43, 68). In line with these observations, intracellular GPR55 may play a role in the regulation of cardiomyocyte contraction.

The accumulating evidence pointing to endolysosomes as intracellular locations where GPCRs initiate signaling (19, 24, 28, 69) prompted us to probe for colocalization of GFP-tagged GPR55 and RFP-tagged Rab7, an endolysosomal-associated small GTPase (46). We noticed extensive colocalization of GPR55 and Rab7. In addition, lysosomal disruption with bafilomycin A1 markedly reduced the fluorescence intensity of both GPR55 and Rab7, suggesting that GPR55 localizes intracellularly at the endolysosomes. GPR55 localization at this site correlates well with its ability to trigger NAADP-dependent Ca²⁺ responses because NAADP-generating enzymes (70, 71) have also been reported to localize at the membrane of acidic organelles (72).

An important discrepancy in the responses initiated by sarcolemmal versus intracellular GPR55 stimulation is that the former depolarized, whereas the latter hyperpolarized the membrane of neonatal ventricular cardiomyocytes. The depolarizing effect of bath-applied LPI was independent of Ca²⁺ signaling, whereas LPI induced GPR55-dependent Ca²⁺ influx via LTCC. A direct effect of LPI on LTCC was considered less likely because it has been reported that, similar to other phospholipids, LPI slightly suppresses LTCC activity (73). The LPI-induced depolarization was not large enough to generate action potentials and, thus, activate LTCC. Rather, the explanation of the LPI-induced effects sits in the fact that cardiac LTCC can be directly activated by Gq (74) because GPR55 is Gq-coupled (17). Conversely, hyperpolarization in response to intracellular GPR55 activation was short-lived and Ca²⁺-dependent. Ca²⁺ extrusion is a fast process, explaining why the hyperpolarization is transient. Similarly, intracellular microinjection of an acknowledged intracrine, angiotensin II, hyperpolarizes ventricular myocytes via intracellular AT₁ receptors (75). Although hyperpolarization may be beneficial in that it may prevent arrhythmias, it could also trigger I₈/I₉, I₆/I₇ is typically a Na⁺/K⁺ inward current associated with hyperpolarization-activated cyclic nucleotide-gated channels, playing a pivotal role in cardiac pacemaking but associated with cardiac hypertrophy and failure when expressed in the ventricles (76). LPI has been shown to have GPR55-independent hyperpolarizing effects on the endothelial cell membrane (77). However, in the presence...
of the GPR55 antagonist ML-193 (36), LPI administration to neonatal ventricular cardiomyocytes produced non-significant responses, supporting GPR55-dependence of the LPI effect in our paradigm.

In animal models of ischemia-reperfusion injury, delletion of the main LPI-synthesizing enzyme cPLA2α has been shown to be either cardioprotective (13) or deleterious to the heart (14). In light of our current findings, the discrepancy between these results may be correlated with the ability of LPI to activate GPR55 either at the sarcoplasmic membrane or within the cardiomyocyte and trigger distinct mechanisms with opposite outcomes.

Collectively, our study shows for the first time that the LPI-responsive receptor GPR55 is involved in the regulation of cardiomyocyte Ca2+ signaling. Furthermore, functional GPR55 can elicit signaling both at the sarcolemma and at the endosomal compartment, and, as shown in Fig. 10, the downstream cascades are distinct. Activation of plasmalemmal GPR55 triggers Ca2+ influx through LTCC and IP3-dependent Ca2+ release that is amplified by CICR via RyR. Independently of this Ca2+ signaling cascade, plasmalemmal GPR55 couples to depolarization of the cardiomyocyte membrane. Intracellular GPR55 activation associates with NAADP-dependent Ca2+ mobilization from acidic-like Ca2+ stores, which is amplified by CICR via RyR, converging to membrane hyperpolarization. This work may serve as a platform for future studies exploring the potential of GPR55 as a therapeutic target in cardiac disorders.

REFERENCES

1. Staton, P. C., Hatcher, J. P., Walker, D. J., Morrison, A. D., Shapland, E. M., Hughes, J. P., Chong, E., Mander, P. K., Green, P. J., Billinton, A., Fulleylove, M., Lancaster, H. C., Smith, J. C., Bailey, L. T., Wise, A., Brown, J. A., Richardson, J. C., and Chessell, I. P. (2008) The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 139, 225–236

2. Whyte, L. S., Ryberg, E., Sims, N. A., Ridge, S. A., Mackie, K., Greasley, P. J., Ross, R. A., and Graier, W. F. (2010) GPR55-dependent and -independent ion signaling in response to lysophosphatidylinositol in endothelial cells. Br. J. Pharmacol. 161, 308–320

3. Moreno-Navarrete, J. M., Catalán, V., Whyte, L., Sánchez, C., and Waldhoer, M. (2011) Minireview. Recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitireceptor GPR55. Mol. Endocrinol. 25, 1835–1848

4. Andradas, C., Caffarel, M. M., Pérez-Gómez, E., Salazar, M., Lorente, M., Díaz-Arteaga, A., Kinduza, A., Sánchez, C., and Sánchez, C. (2011) The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation. Oncogene 30, 245–252

5. Ford, L. A., Roelofs, A. J., Anavi-Goffer, S., Mowat, L., Simpson, D. G., Irving, A. J., Rogers, M. J., Rajnicek, A. M., and Ross, R. A. (2010) A role for L-α-lysophosphatidylinositol/GPR55 system and its potential role in human obesity. Diabetes 61, 281–291

6. Andradas, C., Caffarel, M. M., Pérez-Gómez, E., Salazar, M., Lorente, M., Velasco, G., Guzmán, M., and Sánchez, C. (2011) The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene 30, 245–252

7. Rodríguez, M. L., Grandes, P., Rossignol, R., and Marsicano, G. (2012) Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 protection by binding of CB1-receptor-triggered repression. J. Cell Sci. 121, 1704–1717

8. Henstridge, C. M. (2012) Off-target cannabinoid effects mediated by GPR55. Pharmacology 89, 179–187

9. Zhao, P., and Abood, M. E. (2012) GPR55 and GPR35 and their relationship to cannabinoid and lysophospholipid receptors. Life Sci. 92, 453–457

10. Pérez-Gómez, E., Salazar, M., Serpi, R., Roule, K. C., Cheung, J. Y., O’Leary, E., Bonventre, J. V., and Force, T. (2011) Cytosolic phospholipase A2α protects against ischemia/reperfusion injury in the heart. Clin. Transl. Sci. 4, 236–242

11. Saito, Y., Watanabe, K., Fujikoa, D., Nakamura, T., Obata, J. E., Kawabata, K., Watanabe, Y., Mishina, H., Tamaru, S., Kita, Y., Shimizu, T., and Kujiyama, K. (2012) Disruption of group IVA lysosomal phospholipase A2 attenuates myocardial ischemia-reperfusion injury partly through inhibition of TNF-α-mediated pathway. Am. J. Physiol. Heart Circ. Physiol. 302, H2018–2030

12. Bors, D. M., and Guo, T. (2005) Calcium signaling in cardiac ventricular myocytes. Ann. N.Y. Acad. Sci. 1047, 86–98

13. Brailoiu, G. C., Oprea, T. I., Zhao, P., Abood, M. E., and Brailoiu, E. (2011) Lysophosphatidylinositol signaling in diabetic kidney disease. J. Am. Soc. Nephrol. 22, 29166–29174

14. Rodríguez, M. L., Grandes, P., Rossignol, R., and Marsicano, G. (2012) Intracellular cannabinoid type 1 (CB1) receptors are activated by anandamide. J. Neurosci. 32, 13–16

15. Brailoiu, E., Brailoiu, G. C., Deliu, E., Sharir, H., and Abood, M. E. (2012) 22nd Annual Symposium on the Cannabinoids, Research Triangle Park, NC

16. Brailoiu, G. C., Oprea, T. I., Zhao, P., Abood, M. E., and Brailoiu, E. (2011) Intracellular cannabinoid type 1 (CB1) receptors are activated by anandamide. J. Biol. Chem. 286, 29166–29174

17. Kerkelä, R., Boucher, M., Zaka, R., Gao, E., Harris, D., Piuhkova, L., Song, J., Serpi, R., Roule, K. C., Cheung, J. Y., O’Leary, E., Bonventre, J. V., and Force, T. (2011) Cytosolic phospholipase A2α protects against ischemia/reperfusion injury in the heart. Clin. Transl. Sci. 4, 236–242

18. Henstridge, C. M. (2012) Off-target cannabinoid effects mediated by GPR55. Pharmacology 89, 179–187

19. Zhao, P., and Abood, M. E. (2012) GPR55 and GPR35 and their relationship to cannabinoid and lysophospholipid receptors. Life Sci. 92, 453–457

20. Pérez-Gómez, E., Salazar, M., Serpi, R., Roule, K. C., Cheung, J. Y., O’Leary, E., Bonventre, J. V., and Force, T. (2011) Cytosolic phospholipase A2α protects against ischemia/reperfusion injury in the heart. Clin. Transl. Sci. 4, 236–242

21. Zhu, T., Gobeil, F., Vazquez-Tello, A., Leduc, M., Ribakova, L., Bossolasco, M., Bkaily, G., Peri, K., Varma, D. R., O’Leary, E., and Bonventre, J. V. (2006) Intracellular signaling through lipid mediators and their cognate nuclear G-protein-coupled receptors. A paradigm based on PGE2, PAF, and LPA1 receptors. J. Am. Physiol. Pharmacol. 84, 377–391

22. Bénard, G., Massa, F., Puente, N., Lourenço, J., Belloccio, L., Soria-Gómez, E., Matias, I., Delamarre, A., Metna-Laurent, M., Cannin, A., Herbert-Chatelan, E., Muller, C., Ortega-Guitierrez, S., Martin-Fontecha, M., Klugmann, M., Gugenhuber, S., Lutz, B., Gertsch, J., Chaouloff, F., Lopez-Rodriguez, M. L., Grandes, P., Rossignol, R., and Marsicano, G. (2012) Mitochondrial CB1 receptors regulate neuronal energy metabolism. Nat. Neurosci. 15, 558–564

23. Brailoiu, G. C., Oprea, T. I., Zhao, P., Abood, M. E., and Brailoiu, E. (2011) Intracellular cannabinoid type 1 (CB1) receptors are activated by anandamide. J. Biol. Chem. 286, 29166–29174

24. Henstridge, C. M., Raybaud, K., Kargl, J., Andradas, C., Brown, A. J., Irving, A., Sanchez, C., and Waldhoer, M. (2011) Minireview. Recent developments in the physiology and pathology of the lysophosphatidylinosito-
27. Brailoiu, G. C., Arterburn, J. B., Oprea, T. I., Chitravanshi, V. C., and Brailoiu, E. (2011) Bradycardic effects mediated by activation of G protein-coupled estrogen receptor in rat nucleus ambiguous. Exp. Physiol. 96, 679–691.

28. Deliu, E., Brailoiu, G. C., Mallikankaraman, K., Wang, H., Madesh, M., Undieh, A. S., Koch, W. J., and Brailoiu, E. (2012) Intracellular endothelin type B receptor-driven Ca$^{2+}$ signal elicits nitric oxide production in endothelial cells. J. Biol. Chem. 287, 41023–41031.

29. Deliu, E., Tica, A. A., Motoc, D., Brailoiu, G. C., and Brailoiu, E. (2011) Intracellular angiotensin II activates rat myometrium. Am. J. Physiol. Cell Physiol. 301, C559–565.

30. Grynkiewicz, G., Poenie, M., and Tsien, R. Y. (1985) A new generation of Ca$^{2+}$ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260, 3440–3450.

31. Guse, A. H., Berg, I., da Silva, C. P., Potter, B. V., and Mayr, G. W. (1997) Ca$^{2+}$ entry induced by cyclic ADP-ribose in intact T-lymphocytes. J. Biol. Chem. 272, 8546–8550.

32. Brailoiu, G. C., Arterburn, J. B., Oprea, T. I., Benamar, K., Dun, D. A., Galione, A., and Churchill, G. C. (2012) Intracellular angiotensin II in intact T-lymphocytes. J. Biol. Chem. 287, 37133–37137.

33. Tica, A. A., Dun, E. C., Tica, O. S., Gao, X., Arterburn, J. B., Brailoiu, G. C., Oprea, T. I., and Brailoiu, E. (2011) G protein-coupled estrogen receptor 1-mediated effects in the rat myometrium. Am. J. Physiol. Cell Physiol. 301, C1262–1269.

34. Bräuner, T., Hübner, D. F., and Strasser, R. J. (1984) Comparative measurements of membrane potentials with microelectrodes and voltage-sensitive dyes. Biochim. Biophys. Acta 771, 208–216.

35. Heynen-Genel, S., Dahl, R., Shi, S., Milan, L., Hariharan, S., Sergienko, E., Naylor, E., Arredouani, A., Vasudevan, S. R., Lewis, A. M., Parkesh, R., Novo, A., Smith, L. H., Chung, T. D. Y., Sharir, H., Caron, M. G., Barak, D. A., Galione, A., and Churchill, G. C. (2012) Identification of a chemical probe for NAADP by virtual screening. Nat. Chem. Biol. 5, 220–226.

36. Vites, A. M., and Pappano, A. J. (1994) Distinct modes of inhibition by NAADP-sensitive calcium stores in the endoplasmic reticulum. Annu. Rev. Pharmacol. Toxicol. 34, 344–367.

37. Heynen-Genel, S., Dahl, R., Shi, S., Milan, L., Hariharan, S., Sergienko, E., Naylor, E., Arredouani, A., Vasudevan, S. R., Lewis, A. M., Parkesh, R., Novo, A., Smith, L. H., Chung, T. D. Y., Sharir, H., Caron, M. G., Barak, D. A., Galione, A., and Churchill, G. C. (2012) Identification of a chemical probe for NAADP by virtual screening. Nat. Chem. Biol. 5, 220–226.

38. Vites, A. M., and Pappano, A. J. (1994) Distinct modes of inhibition by NAADP-sensitive calcium stores in the endoplasmic reticulum. Annu. Rev. Pharmacol. Toxicol. 34, 344–367.

39. Heynen-Genel, S., Dahl, R., Shi, S., Milan, L., Hariharan, S., Sergienko, E., Naylor, E., Arredouani, A., Vasudevan, S. R., Lewis, A. M., Parkesh, R., Novo, A., Smith, L. H., Chung, T. D. Y., Sharir, H., Caron, M. G., Barak, D. A., Galione, A., and Churchill, G. C. (2012) Identification of a chemical probe for NAADP by virtual screening. Nat. Chem. Biol. 5, 220–226.

40. Janowski, E., Berríos, M., Cleemann, L., and Morad, M. (2010) Developmental aspects of cardiac Ca$^{2+}$ signaling. Interplay between RyR- and IP3R-gated Ca$^{2+}$ stores. Am. J. Physiol. Heart Circ. Physiol. 298, H1939–1950.

41. Saini, H. K., and Dhalla, N. S. (2006) Modification of intracellular calcium concentration in cardiomyocytes by inhibition of sarcosomel Na$^{+}$/H$^{+}$ exchange. Am. J. Physiol. Heart Circ. Physiol. 291, H2790–2800.

42. Bootman, M. D. (2008) Emerging roles of inositol 1,4,5-trisphosphate signaling in healthy and failing hearts. Circ. Res. 107, 147–157.

43. Janowski, E., Berríos, M., Cleemann, L., and Morad, M. (2010) Developmental aspects of cardiac Ca$^{2+}$ signaling. Interplay between RyR- and IP3R-gated Ca$^{2+}$ stores. Am. J. Physiol. Heart Circ. Physiol. 298, H1939–1950.

44. Lewin, K. H., and Dhall, N. S. (2006) Modification of intracellular calcium concentration in cardiomyocytes by inhibition of sarcosomel Na$^{+}$/H$^{+}$ exchange. Am. J. Physiol. Heart Circ. Physiol. 291, H2790–2800.

45. Lee, H. C. (2001) Physiological functions of cyclic ADP-ribose and NAADP as calcium messengers. Annu. Rev. Pharmacol. Toxicol. 41, 317–345.

46. Patel, S., Marchant, J. S., and Brailoiu, E. (2010) Two-pore channels. Regulation of membrane potentials with microelectrodes and voltage-sensitive dyes. Biochim. Biophys. Acta 1809, 85–99.

47. Janowski, E., Berríos, M., Cleemann, L., and Morad, M. (2010) Developmental aspects of cardiac Ca$^{2+}$ signaling. Interplay between RyR- and IP3R-gated Ca$^{2+}$ stores. Am. J. Physiol. Heart Circ. Physiol. 298, H1939–1950.
67. Jungsuwadee, P., Nithipongvanitch, R., Chen, Y., Oberley, T. D., Butterfield, D. A., St Clair, D. K., and Vore, M. (2009) Mrp1 localization and function in cardiac mitochondria after doxorubicin. *Mol. Pharmacol.* **75**, 1117–1126

68. Macgregor, A., Yamasaki, M., Rakovic, S., Sanders, L., Parkesh, R., Churchill, G. C., Galione, A., and Terrar, D. A. (2007) NAADP controls cross-talk between distinct Ca²⁺ stores in the heart. *J. Biol. Chem.* **282**, 15302–15311

69. Calebiro, D., Nikolaev, V. O., and Lohse, M. J. (2010) Imaging of persistent cAMP signaling by internalized G protein-coupled receptors. *J. Mol. Endocrinol.* **45**, 1–8

70. Cosker, F., Cheviron, N., Yamasaki, M., Menteyne, A., Lund, F. E., Moutin, M. J., Galione, A., and Cancela, J. M. (2010) The ecto-enzyme CD38 is a nicotinic acid adenine dinucleotide phosphate (NAADP) synthase that couples receptor activation to Ca²⁺ mobilization from lysosomes in pancreatic acinar cells. *J. Biol. Chem.* **285**, 38251–38259

71. Kim, S. Y., Cho, B. H., and Kim, U. H. (2010) CD38-mediated Ca²⁺ signaling contributes to angiotensin II-induced activation of hepatic stellate cells. Attenuation of hepatic fibrosis by CD38 ablation. *J. Biol. Chem.* **285**, 576–582

72. Davis, L. C., Morgan, A. J., Ruas, M., Wong, J. L., Graeff, R. M., Poustka, A. J., Lee, H. C., Wessel, G. M., Parrington, J., and Galione, A. (2008) Ca²⁺ signaling occurs via second messenger release from intraorganelle synthesis sites. *Curr. Biol.* **18**, 1612–1618

73. Ben-Zeev, G., Telias, M., and Nussinovitch, I. (2010) Lysosphospholipids modulate voltage-gated calcium channel currents in pituitary cells. Effects of lipid stress. *Cell Calcium* **47**, 514–524

74. Weiss, S., Doan, T., Bernstein, K. E., and Dascal, N. (2004) Modulation of cardiac Ca²⁺ channel by Gq-activating neurotransmitters reconstituted in *Xenopus* oocytes. *J. Biol. Chem.* **279**, 38251–38259

75. De Mello, W. C. (2011) Intracrine action of angiotensin II in the intact ventricle of the failing heart. Angiotensin II changes cardiac excitability from within. *Mol. Cell Biochem.* **358**, 309–315

76. Stillitano, F., Sartiani, L., DePaoli, P., Mugelli, A., and Cerbai, E. (2008) Expression of the hyperpolarization-activated current, I(h), in cultured adult rat ventricular cardiomyocytes and its modulation by hypertrophic factors. *Pharmacol. Res.* **57**, 100–109

77. Bondarenko, A. I., Malli, R., and Graier, W. F. (2011) The GPR55 agonist lysophosphatidylinositol acts as an intracellular messenger and bidirectionally modulates Ca²⁺-activated large-conductance K⁺ channels in endothelial cells. *Pflugers Arch.* **461**, 177–189